BCAL Diagnostics

BCAL Diagnostics Dividend Coverage

Dividend Coverage Ratio of BCAL Diagnostics (BDX.AX) as of Oct 17, 2026.

Dividend Coverage

-

Last updated:

Dividend Coverage Ratio of BCAL Diagnostics is 2026 - . Dividend Coverage Ratio of BCAL Diagnostics was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BCAL Diagnostics Stock analysis

What does BCAL Diagnostics do? BCAL Diagnostics Ltd, based in Sydney, Australia, operates in the Health Care sector within the Biotechnology industry. The company develops innovative blood screening tests for early breast cancer detection, focusing on a lipid biomarker-based approach known as the BCAL test. This technology complements existing imaging methods like mammograms and aims to support screening and monitoring for women of all ages and backgrounds. BCAL Diagnostics has partnered with Precion Inc. to advance clinical trials and regulatory approvals for its diagnostic solutions. BCAL Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BCAL Diagnostics stock

On Eulerpool you can find the complete historical development of Dividend Coverage Ratio BCAL Diagnostics since 2006 – with annual values, charts, and detailed analysis.

The dividend coverage ratio measures how many times dividends can be covered by net income. Higher coverage suggests more sustainable dividend payments.

Dividend Coverage Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Coverage Ratio's BCAL Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — BCAL Diagnostics

All Key Metrics — BCAL Diagnostics